



Cervical Cancer Consortium Europe

2nd European Conference on Cervical Cancer Screening

Tübingen (Germany), September 19-20, 2005

***European Guidelines for Quality Assurance in
Cervical Cancer Screening***

M. ARBYN ^{1,2}

¹*European Cancer Network*

²*Scientific Institute of Public Health, Brussels*



Cancer Screening policy in the EU

(Council recommendation)



Conference on Screening and Early Detection of Cancer

November 18-19th, 1999, Vienna

- **Development of a European Strategy**
- **Consensus reached: Advisory Committee on Cancer Prevention: *Eur J Cancer* 2000; 36: 1473-8.**



Vienna Conference, 1999

- **Evidence: organised screening can reduce cause-specific mortality from:**

- **Breast cancer:**

- ◆ mammography, women 50-69 years, 2-year interval

- **Cervical cancer:**

- ◆ Pap smear, women from $\geq 20 \leq 30$ to ≥ 60 years, 3-5 year interval

- **Colo-rectal cancer:**

- ◆ FOBT, men & women 50-74 years, 1-2 year interval



Summary of the Council recommendation (2 December 2003)

- **Based on the Vienna consensus**
- **Argumentation updated**
- **Screening policy less detailed**
 - Mammography for women 50-69 years
 - Pap test for women starting at 20-30 years
 - Colo-rectal cancer screening for man & women 50-74 years
- **Screening only offered in organised programmes:**
 - Monitoring & QA at all levels: invitation, participation, screen test, follow-up of screen+, treatment, after-care, registration, data-linkage (privacy!)



Summary of the Council recommendation (2)


- **Screening accordance with evidence-based guidelines**
- **Research on new screening methods (RCT, public health relevant outcomes: mortality or established surrogate endpoints)**
- **Assessment of level of evidence concerning effects of new methods by pooling results of trials**



Burden of CC in Europe

W-Age standardised mortality from and incidence of cervical cancer

Member states of the EU (2002)




Ferlay J, et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, Version 2.0 IARC CancerBases No. 5. Lyon, IARC, 2004.



Cervical cancer mortality in Europe

**W-Age Standardised Rate
(/100 000 women-years)**

0 to 1.49	(2)
1.5 to 2.99	(10)
3.0 to 4.49	(8)
4.5 to 5.99	(9)
6.0 to 7.49	(8)
7.5 to 8.99	(3)
9.0 to 11.49	(2)



**Source:
Globocan 2000, IARC**
Map produced by M. Arbyn



Cervical Cancer Screening Guidelines



Guidelines for QA in CC screening: history

- **First edition: Coleman et al, Eur J Cancer 1993, 29A, suppl 1, 1-29.**
- **Conception of a new task for the European Network for CC Screening (ENCCN): Ormyla, September 2001**
- **Main objective of the last contract between ECCSN-DG Sanco (Dec 2002-Dec 2003)**



History (2)

- **Luxembourg, 16-17 October, 2002:**
 - **Table of contents**
 - **Chapter leaders appointed**
 - **Time schedule**
- **Adittional meetings:**
 - ◆ **Copenhagen, March 2003, chapter 2**
 - ◆ **Helsinki, June 2003, 1st draft**
 - ◆ **Ormyla, September 2003, 2nd draft**
- **Final report: 3th draft, 15 December 2003**



Guidelines for QA in CC screening



Coordination: Bavarian Cancer Society, Munich

Members of ECCSN, invited experts

With the financial support of:



**EUROPEAN COMMISSION
HEALTH & CONSUMER PROTECTION
DIRECTORATE-GENERAL**

Directorate G - Public Health, Luxembourg



Table of contents: CH 1-6

- 0. Executive summary**
- 1. Introduction**
- 2. Epidemiological guidelines for quality assurance in cervical screening**
- 3. Methods and techniques of cervical screening**
 - **Annex 1: Collection of adequate Pap smears**
 - **Annex 2: European cytological reporting systems**
- 4. Laboratory guidelines for cervical screening**
- 5. Quality assurance practices in screening laboratory**
- 6. Certification of the screening process and staff skills**



Table of contents: CH 7-12

- 7. Quality assurance guidelines for pathology in cervical screening**
- 8. Management of women with cervical cytological abnormalities**
- 9. Data collection on treatment and follow-up of screen-detected lesions**
- 10. Guidelines for training**
- 11. Summary table of key performance indicators**
- 12. Summary table for the screening programme**



Current product

- **Final report (Luxembourg, December 2003, 3th draft)**
- **2nd draft (Ormyla, Sep 2003): available on internet**
<http://www.cancer-network.de/>
- **3th draft: chapter leaders**



Meanwhile

- **Conference EU guidelines on Breast Cancer Screening (Budapest, 23-25 September 2004)**
- **Presentation of the draft status of the guidelines**
 - **Support adaptation to the situation 2004**
 - **10 new EU member states (>> higher burden)**
 - **Approval/validation by a EU mandated forum**
 - **Final style editing**
 - **Publication**
- **25 Sep 2005: demand of the EU Commission to finalise CC screening guidelines**



Guidelines:

Re-picking up the thread

- **Mandate from the Commission**
- **Support from IARC**
- **Nearly all members ECCSN accepted collaboration**
- **External review meeting (June 2004, Lyon, IARC)**
- **Rewriting of the chapter on QA in cyto laboratories**
- **Improving & updating of other chapter**
- **Appendices on communication, HPV infection, HPV vaccination**



To conclude:

EU guidelines

- **To be finalised near end 2005**
- **Publication by the EU Commission start 2006**